Objective. Cytokine-induced hepatic serum amyloid A (SAA) synthesis is the critical step in the pathogenesis of AA amyloidosis secondary to rheumatoid arthritis (RA). This study was conducted to provide more insight into the mechanism of SAA production in hepatocytes and its regulation. Methods. Primary cultured normal human hepatocytes were stimulated with cytokines (IL-1b, TNF-a and IL-6) and the culture supernatants were analysed for the production of SAA. Human hepatocytes, treated or not treated with A77 1726, were stimulated with IL-1b and the cellular lysates were analysed by immunoblot using anti-phospho-specific mitogen-activated protein kinase (MAPK) and IjB-a. Acute phase-SAA (SAA1) mRNA expression was analysed by reverse transcriptionpolymerase chain reaction. Results. IL-1b is a most potent inducer of SAA in normal hepatocytes. A77 1726 suppressed the production of SAA in human hepatocytes activated by IL-1b in a dose-dependent manner (0-50 lM). A77 1726 inhibited IL-1b-induced p38 and c-Jun N-terminal kinase 1/2 (JNK1/2) activation, whereas A77 1726 did not affect IL-1b-induced NF-jB activation in hepatocytes. Conclusion. These results indicate that MAPK signalling pathways are critical in IL-1b-induced hepatic SAA synthesis. Leflunomide may suppress SAA synthesis by affecting these pathways and may therefore have some beneficial effect on AA amyloidosis secondary to RA.
Cells
Human primary hepatocytes were purchased from Cell Systems (Kirkland, WA, USA). The cells were cultured in a basal medium composed of Ham's F-12 and Leibovitz L-15 (1:1) medium (Invitrogen, Carlsbad, CA, USA), 0.2% (v/v) bovine serum albumin, 5 mM glucose (Wako Chemical, Osaka, Japan), 10 À8 M dexamethasone (Wako) and 10 À8 M bovine insulin (Invitrogen) supplemented with 10% (v/v) fetal calf serum (FCS, Gibco, Grand Island, NY). These hepatocyte preparations were less than 0.1% reactive with CD68 monoclonal antibodies (eBioscience, San Diego, CA), indicating that these cells were free of monocytes/macrophages.
Assessment of cell viability
Cell viability was assessed using methyl thiazolyl tetrazolium (MTT) staining. Cell cultures (100 l) of containing 1 Â 10 4 cells were plated in the wells of 96-well culture plates. After incubation with A77 1726 for 24 h, 100 l of MTT solution (2.5 mg/ml) was added. After incubation at 37 C for 4 h, 100 l of acid isopropanol (0.04 N HCl in isopropanol) was added and mixed gently with the cell suspension, and optical density at 560 nm was determined with an enzyme-linked immunosorbent assay reader.
Immunoblot analysis
Whole-cell lysates were prepared from IL-1-stimulated hepatocytes using Triton lysis buffer containing protease and phosphatase inhibitor (1% Nonidet P 40, 50 mM Tris, pH 7.5, 100 mM NaCl, 50 mM NaF, 5 mM EDTA, 20 mM -glycerophosphate, 1.0 mM sodium orthovanadate, 10 g/ml aprotinin and 10 mg/ml leupeptin). One hundred micrograms of protein was electrophoresed on 10% sodium dodecyl sulphate-polyacrylamide gels. The fractionated proteins were transferred to nitrocellulose membranes and probed by anti-IB-, phospho-ERK1/2, phospho-p38 and phospho-JNK1/2 antibodies (1:1000 dilution; Biosource, Camarillo, CA, USA). Hepatocyte culture supernatants were also electrophoresed on 14% polyacrylamide gels. The fractionated proteins were transferred to a nitrocellulose membrane (pore size 0.2 m; Bio-Rad, Hercules, CA, USA) and probed with rabbit anti-SM antibodies (1:2000 dilution) and developed using an enhanced chemiluminescence system (Amersham, Arlington Heights, IL, USA).
RNA preparation and RT-PCR assay
Total cellular RNA was extracted from hepatocytes using guanidium thiocyanate and phenol (RNAzol B; Cinna/Biotek Labs, Friendswood, TX). First-strand cDNA was synthesized by reverse transcription (RT) at 45 C for 45 min in a 50 l reaction mixture containing 1 g of total RNA and MuLV reverse transcriptase (Invitrogen). After denaturing at 99 C for 5 min followed by cooling at 5 C, the cDNA was amplified using the polymerase chain reaction (PCR). Two microlitres of denatured cDNA was amplified in a 20 l final volume containing 1 U Taq DNA polymerase (Gibco BRL, Gaithersburg, MD, USA), 1 M of each primer, Taq polymerase buffer, 1.5 mM MgCl 2 and 1.5 mM of each dNTP. PCR was performed in a thermal cycler (PerkinElmer-Cetus, Foster City, CA, USA) using a program of 30 cycles of 95 C for 1 min, 55 C for 1 min, and 72 C for 1 min with a final 10 min extension at 72 C. The amplified products were subjected to electrophoresis on 2% agarose gel.
The specific primers used were as follows: for SAA1, 5 0 -CAGACAAATACTTCCATGCT-3 0 (forward) and 5 0 -ATTGTG TACCCTCTCCCCC-3 0 (reverse). The predicted size of the fragment was 303 bp; for -actin, 5
0 -GACGAGGCCCAGAGC AAGAGAG-3 0 (forward) and 5 0 -ACGTACATGGCTGGGGTG TTG-3 0 (reverse). The predicted size of the fragment was 236 bp.
Plasmids and transfection
pNFB-SEAP (Clontech Laboratories, Palo Alto, CA, USA) was designed to monitor the activation of NFB and NFB-mediated signal transduction pathways. pNFB-SEAP contained four tandem copies of the B4 enhancer fused to the HSV-TK promoter. pTAL-SEAP (Clontech Laboratories) was used as a negative control to determine the background signals associated with the culture medium. Cells were grown to approximately 50% confluence on 30-mm plates. Transfections were done using calcium phosphate regents and following the manufacturer's instructions (Clontech Laboratories), and the cells were treated as described above. Chemiluminescence detection of the SEAP activity was performed according to the manufacture's instructions (Clontech Laboratories) using a plate fluorometer (Berthold, Bad Wildbach, Germany).
Results

Cytokine-induced SAA production in hepatocytes
To examine whether SAA can be produced from normal hepatocytes, primary cultured human hepatocytes were stimulated by cytokines. Human hepatocytes were stimulated with IL-1, TNF-or IL-6, and the culture supernatants were subjected anti-SAA immunoblot analysis. As shown in Fig. 1 , the stimulation of SAA protein production was significantly induced in IL-1-stimulated hepatocytes compared with that in hepatocytes stimulated by TNF-or IL-6. These observations suggest that IL-1 is a key cytokine for the regulation of the magnitude of SAA production in human hepatocytes in vitro.
IL-1-induced MAPK and NF-B activation in hepatocytes
We then focused on the IL-1-mediated SAA synthesis cascade in human hepatocytes. Upon binding of IL-1 to its receptor, receptor-mediated signals eventually activate MAPK and NF-B to produce inflammatory mediators [14] . As shown in Fig. 2 , IL-1 stimulation resulted in 1B-degradation, which suggests the activation of NF-B. IL-1 stimulation also induced the phosphorylation of MAPK (ERK1/2, p38, and JNK1/2), demonstrating the activation of the kinases (Fig. 3) . 
Inhibition of SAA induction by A77 1726 in hepatocytes
Leflunomide is an isoxazole derivative that has been proved to be efficacious in the treatment of RA. Several investigators have demonstrated that leflunomide is a patent inhibitor of MAPK and NF-B [15, 16] . The above findings may suggest that the potent inhibitors for MAPK and NF-B can be capable of modulating IL-1-induced SAA synthesis in hepatocytes. We examined the effects of A77 1726, leflunomide's active metabolite, on IL-1-stimulated SAA production in human hepatocytes. As shown in Fig. 4 , A77 1726 significantly inhibited SAA production in IL-1-stimulated human hepatocytes at concentrations of 10-50 M. The attenuating effects of A77 1726 on SAA production were not due to a toxic effect, because cell respiration analysed by MTT staining was not affected by this drug (data not shown).
To examine whether A77 1726 blocked SAA induction at the transcriptional level, we analysed A-SAA mRNA expression in human hepatocytes by RT-PCR. As shown in Fig. 5, SAA1 mRNA expression was markedly induced in IL-1-stimulated human hepatocytes. This IL-1-stimulated SAA1 mRNA expression was inhibited by 50 M of A77 1726.
A77 1726 modifies the phosphorylation state of the MAPK activated by IL-1
Next, we investigated the molecular mechanism by which A77 1726 inhibited SAA synthesis in hepatocytes. We evaluated 1B-proteolysis. The protein levels of 1B-in IL-1-stimulated quiescent hepatocytes were measured by immunoblot analysis (Fig. 6) . IL-1 stimulation induced substantial 1B-degradation. A77 1726 treatment did not influence this 1B-degradation. The transcriptional activity of NF-B was also examined. To this end, hepatocytes were transiently transfected with NF-B-SEAP. Then, the transfectants were pretreated with A77 1726 for 12 h, a treatment which was followed by stimulation with IL-1 for 12 h. As shown in Fig. 7 , no suppressive effect of A77 1726 on NF-B-dependent transcriptional activity was observed.
We examined the effects of A77 1726 on IL-1-induced MAPK activation in hepatocytes. Quiescent hepatocytes were incubated with 0$50 M of A77 1726, an active metabolite of leflunomide, for 12 h. Hepatocytes pretreated with A77 1726 were then stimulated with IL-1 for 15 min. The cellular lysates were then analysed by immunoblots using anti-phospho-specific MAPK antibodies. The A77 1726 pretreatment did not affect the phosphorylation status of ERK1/2, whereas IL-1-induced p38 and JNK1/2 phosphorylation was inhibited by pretreatment with A77 1726 (Fig. 8) .
Discussion
The overexpression of SAA during chronic inflammation is linked to the pathophysiology of RA and AA amyloidosis [1] . The prognosis of RA patients with AA amyloidosis is still poor and the 50% survival rate ranges between 2 and 4 yr [17] . Circulating SAA is the precursor of AA amyloid deposited in the tissue [4] . Reduction of the amount of precursor protein, which arrests further deposition of amyloid, is currently the most rational approach for the management of AA amyloidosis [6] . Normalization of SAA to the baseline values can be achieved by the complete abolishment of hepatic SAA synthesis. Because of its link with AA amyloidosis, the mechanism of SAA induction has been the subject of intensive investigation. However, only limited data are available on the production of SAA in normal human hepatocytes. We therefore investigated the mechanism of cytokine-induced SAA synthesis and its regulation, using normal human hepatocytes. Previous studies using primary hepatocytes, hepatoma cell lines and transfected cells have indicated that SAA synthesis can be induced by IL-6, IL-1 and TNF- [18] . In this study, we showed that, among the cytokines studied, IL-1 is the most potent inducer of SAA protein synthesis in normal human hepatocytes. Our results are consistent with those of previous reports demonstrating that the effect of IL-1 is substantially more potent than that of the other two cytokines [19] . However, it should be noted that different human hepatoma cell lines differ in their ability to synthesize SAA in response to individual cytokines. Upon the binding of IL-1 to the IL-1 receptor (IL-1R), MyD88, an adapter protein, links to IL-1R-associated protein kinase (1RAK) and 1RAK is phosphorylated [20] . Phosphorylated 1RAK dissociates from the receptor complex and activates TNF receptor-associated factor 6 (TRAF-6) [21] . Subsequently, TRAF-6 activates MAPK and NF-B to induce target gene expression [14] .
To elucidate IL-1 signalling in SAA synthesis, we investigated MAPK and NF-B activation in human hepatocytes. Consistent with the previous findings, our data indicated that IL-1 stimulation resulted in the activation of extracellular signal-related kinase 1/2, p38 and JNK1/2 in hepatocytes. NF-B has also been shown to be activated by IL-1 stimulation, based on the rapid degradation of 1B-observed here and elsewhere.
To extend our results further, we addressed the question of whether IL-1-mediated SAA induction could be regulated by the modulation of these signalling pathways. The novel result is that an active metabolite of leflunomide, A77 1726, almost completely suppressed IL-1-induced SAA protein synthesis in normal human hepatocytes. The primary mode of action of leflunomide is thought to be the inhibition of pyrimidine biosynthesis [22] , but other mechanisms are involved as well [23] . Some reports have suggested that leflunomide is a potent inhibitor of NF-B and MAPK [15, 16] , which are also implicated in A-SAA gene transcription [12] . An unexpected result from the NF-B activation study was that although the transcriptional activation of NF-B occurred in IL-1-stimulated hepatocytes, the inhibitory effect of A77 1726 on NF-B was not observed. Furthermore, A77 1726 did not affect IL-1-triggered 1B-degradation in these human hepatocytes. Although we have not yet identified in detail the mechanism involved in the A771726-mediated suppression of SAA synthesis, several possibilities can be suggested. Recently, a novel cytokineinducible transcription factor, designated SAA-activating factor-1 (SAF-1), was shown to be involved in A-SAA gene expression [24] . SAF-1 is a zinc finger transcription factor that is activated by many mediators, including IL-1 [24] . It was demonstrated that the MAPK signalling pathway regulated the DNA-binding activity of SAF-1 [25] . To determine whether the inhibitory effects of A77 1726 on SAA induction can be attributed to the inhibition of MAPK activation, we examined the effects of A77 1726 on MAPK in IL-1-stimulated hepatocytes. Our results revealed that A77 1726 suppressed IL-1-induced p38 and JNK1/2 activation. In this study, we did not identify the direct mechanism involved in leflunomide-mediated SAA suppression; however, in hepatocytes the MAPK pathway appears to be critical for IL-1-induced SAA induction, and NF-B may not be involved in SAA induction in normal human hepatocytes. In addition to SAF-1, CCAAT enhancer binding protein (C/EBP) has been shown to play a major role in the transcriptional induction of A-SAA genes [26] . The C/EBP family is activated through the MAPK pathway [27] . It is also possible that A77 1726 inhibited IL-1-induced SAA synthesis by affecting C/EBP.
It is thought that the adequate control of inflammation in the course of RA may prevent the development of AA amyloidosis [28] . Cytotoxic drugs, such as chlorambucil, have been thought to induce the remission of arthritis and improve the prognosis of AA amyloidosis in both juvenile and adult RA [29, 30] . However, counselling should be undertaken before these drugs are prescribed, because of the unlicensed induction and its adverse effects. Taken together, our results suggest that new anti-rheumatic drugs suppressing MAPK pathways may provide beneficial effects in the prevention of AA amyloidosis by suppressing hepatic SAA synthesis, in addition to providing anti-inflammatory effects in RA patients.
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